breast cancer

[Cell Death & Disease] Researchers revealed that transmembrane protein 97 was a positive modulator of canonical Wnt signaling which was implicated in the tumorigenesis of breast cancer.

[Clinical and Experimental Medicine] The authors investigated pseudopodium-enriched atypical kinase 1 (PEAK1) expression in breast cancer and its role in breast cancer cells in vitro and in vivo and analyzed the relationship with clinicopathological status and chemotherapy resistance.

[Pharmacology & Therapeutics] Investigators discuss the roles of ferroptosis-associated modulators glutathione, glutathione peroxidase 4, iron, nuclear factor erythroid-2 related factor-2, superoxide dismutases, lipoxygenase and coenzyme Q in breast cancer and provide evidence that ferroptosis inducers eliminate breast cancer cells.

[Gilead Sciences, Inc.] Gilead Sciences, Inc. announced that Health Canada has approved Trodelvy® for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received two or more prior therapies, at least one of them for metastatic disease.

[Cell Division] The authors discuss asymmetric cell division in breast/mammary stem cells and implications on further research, with focus on the role asymmetric cell division may play in breast cancer.

[Telix Pharmaceuticals] Telix Pharmaceuticals Limited announced that a first patient has been dosed in a Phase II study of TLX250-CDx in patients with TNBC.